FDA Revising Accelerated Approval Standard In Oncology; Biomarkers Sought
Executive Summary
FDA is changing its accelerated approval guidelines to allow for approval of several different oncologic agents for the same indication under Subpart H procedures, Commissioner McClellan said during the American Society of Clinical Oncology annual meeting in Chicago May 31
You may also be interested in...
FDA Gives “Fast Track” Wide Lane; Guidance Sets Few Limits On Criteria
FDA broadly defines the circumstances under which drugs and biologics can be approved under expedited approval mechanisms in a guidance published July 22
FDA Gives “Fast Track” Wide Lane; Guidance Sets Few Limits On Criteria
FDA broadly defines the circumstances under which drugs and biologics can be approved under expedited approval mechanisms in a guidance published July 22
FDA May Ask Congress For Funds To Boost Translational Research For Drugs
FDA is understood to be considering whether legislation could be useful to help promote translational research for pharmaceuticals